---
title: "Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288773686.md"
description: "Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics (KZIA), raising the 12-month price target to $30. The upgrade reflects strengthened confidence in Kazia's PI3K/AKT/mTOR strategy, supported by Celcuity's positive Phase 3 results and de-risked mechanisms. Additionally, H.C. Wainwright maintained a Buy rating with an $18 price target."
datetime: "2026-06-04T18:45:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288773686.md)
  - [en](https://longbridge.com/en/news/288773686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288773686.md)
---

# Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

Maxim Group analyst Naz Rahman has reiterated their bullish stance on KZIA stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Naz Rahman has given his Buy rating due to a combination of factors relating to both the clinical and market backdrop for paxalisib. He sees Celcuity’s statistically significant Phase 3 results with its PI3K/mTOR inhibitor as strengthening confidence in the entire class, and by extension validating Kazia’s approach with an orally administered PI3K/AKT/mTOR agent that has shown encouraging tolerability without the high neutropenia rates seen in some IV regimens.

Rahman also notes that Celcuity’s pending PDUFA decision and growing deal activity in the PI3K/mTOR arena suggest rising strategic value for high-quality assets in this pathway. With Kazia expanding its triple-negative breast cancer trial and the broader mechanism being further de-risked, he has reduced his revenue risk assumptions for paxalisib and raised his 12‑month price target to $30, reinforcing his Buy recommendation on the stock.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

### Related Stocks

- [KZIA.US](https://longbridge.com/en/quote/KZIA.US.md)
- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)
- [KZA.AU](https://longbridge.com/en/quote/KZA.AU.md)

## Related News & Research

- [Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC](https://longbridge.com/en/news/289025273.md)
- [Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million](https://longbridge.com/en/news/289098423.md)
- [Is Mettler-Toledo Stock Underperforming the S&P 500?](https://longbridge.com/en/news/289497288.md)
- [What's Going On With Celcuity Stock On Tuesday?](https://longbridge.com/en/news/288463475.md)
- [Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer | KZIA Stock News](https://longbridge.com/en/news/287627288.md)